Could smarter trial design unlock better dementia treatments?

NCT ID NCT05592678

First seen May 01, 2026 · Last updated May 16, 2026 · Updated 3 times

Summary

This study explores better methods for running clinical trials in dementia and cognitive decline. Researchers will use a new measurement called 'δ' that combines thinking ability and daily function, along with blood protein levels, to see if they can predict who will respond to the Alzheimer's drug donepezil. About 200 older adults with mild cognitive impairment or Alzheimer's and their caregivers will participate. The goal is not to test a new treatment, but to improve how future trials measure success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Univeristy of Texas Health Science Center at San Antonio (UTHSCSA)

    RECRUITING

    San Antonio, Texas, 78229-3900, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.